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Running Head     ‘Prognostic implications of a negative flow cytometric MRD test when 
refractory by morphology in AML’ 
  
 To the Editor: 
 
 
A morphology exam incorporating a differential count of a recommended 500 nucleated bone marrow 
cells (Dohner, et al 2017)  continues to be requirement for an acute myeloid leukemia patient to be 
classified as in complete remission by International Working Group (IWG) response criteria (Cheson, 
et al 2003).   It has however become increasingly standard to perform morphology and flow cytometry 
in parallel to assess remission.  Like morphology, flow cytometry (MFC) assays for residual leukemia 
will enumerate blast percentage for the 5% threshold but additionally provide greater accuracy and 
the possibility to discriminate leukemic from normal blasts at a sensitivity of 10-3 to 10-4 (Schuurhuis, 
et al 2018).   Both approaches require training, experience and a representative bone marrow sample 
for reliable results and have limitations that may potentially contribute to discrepant results and inter-
laboratory variation (Walter 2018).  It has been suggested that a morphology assessment of response 
is less specific than flow cytometry when rebound normal regeneration following induction 
chemotherapy results in more than 5% normal blasts, (predominantly a feature of pediatric marrows).  
Administration of G-CSF or dysplastic changes from stressed regeneration can also add difficulty to 
morphological differential counts.     
  Outcome data from multiple previous studies applying flow cytometry to measure residual disease 
in morphological complete remission (Schuurhuis, et al 2018) have contributed to the European 
LeukemiaNet (ELN) recommendation that morphological CR without measurable residual disease 
(CRMRD-) be included as a defined response endpoint for AML (Dohner, et al 2017).  CRMRD- by flow 
cytometry is associated with a significantly better overall survival than morphological CR/CRi for 
younger adults even after first induction (63% versus 52% at five years)(Freeman, et al 2018) as 
previously shown for older patients treated intensively (Freeman, et al 2013).    
Considering the prognostic relevance of a negative MRD test (MRD-) in patients with ≥5% 
morphological blasts, flow cytometric measurements of persistent leukemia were compared with 
morphological IWG criteria in two separate pediatric trial cohorts reported over 5 years ago (Inaba, et 
al 2012, Loken, et al 2012).  The two studies defined a positive MRD test differently (≥0.1% (Inaba, et 
al 2012)  versus any MRD detected (Loken, et al 2012)) but in both cohorts, the subgroup with ≥5% 
morphological blasts but MRD- by flow cytometry post first induction had a similar outcome to those 
who achieved a CRMRD-. (Inaba, et al 2012, Loken, et al 2012).  Thus, at least for pediatric bone 
marrows, from this data morphological blast counts add no predictive value for outcome to a negative 
flow cytometric MRD test.  Should this also be the case for adults, then a negative flow cytometric 
MRD test in a representative bone marrow sample could obviate the requirement for a morphology 
blast count to define CR following induction.   
However, we observe that there is insufficient data in adult AML to corroborate flow cytometry being 
more predictive than morphology for response when morphological blast percentage exceeds the CR 
threshold.  In particular, there has been no formal evaluation in adult trials of the outcome of patients 
who have discrepant refractory / MRD- results at induction response assessment.  Moreover, the 
frequency of these discrepancies in regenerating adult bone marrow following induction 
chemotherapy remains uncertain but is likely to be less common than in the pediatric setting.  In a 
retrospective analysis of mainly adult patients only 4% of BM samples classified as refractory by 
morphology at various treatment time-points were MRD negative by flow cytometry (Ouyang, et al 
2015); a much lower frequency than that observed post first induction in the pediatric studies (26% 
(Loken, et al 2012) and 38% (Inaba, et al 2012)).  We also note from the recent article by Zhou et al 
that in their series of 87 patients with confirmed relapse by morphology, all were MRD+ by flow 
cytometry(Zhou, et al 2017).  Consequently, potential discrepancies between morphology and flow 
cytometry are most likely when testing for response rather than for relapse.  
 
This has prompted us to examine the data for discrepant morphology and flow cytometric MRD results 
post first induction in the three adult AML trials for which outcomes by flow cytometric MRD status in 
CR have previously reported by the HOVON (Terwijn, et al 2013) and NCRI (Freeman, et al 2018, 
Freeman, et al 2013) trial groups (Table 1).  Flow cytometric MRD samples were more likely to be 
hemodilute than morphology as not prioritised for ‘first pull’ bone marrow.  In these trials, the 
morphology and flow cytometric MRD results were independently reported.  Only a few adults from 
all three trials were reported to be in CR but had ≥5% leukemic blasts by flow cytometry (n=25) (Table 
1); Most (88%) survived less than 2 years. 
For adults not in CR, frequencies of MRD negativity (defined as <0.1% by HOVON or as no detectable 
MRD by NCRI) post first induction ranged from ~10% to ~31% with the highest in the HOVON/SAKK 
younger adult trial which evaluated G-CSF priming in induction.  In all three cohorts of refractory adults 
with MRD data, better outcomes were observed in the refractory/MRD- patients, although small 
numbers limit analysis.  Moreover, 3 year survival rates (Table 1) were not inferior to those of patients 
in morphological CR post first induction (3 year OS if CR/CRi, 59% in NCRI AML17, 67% in HOVON/SAKK 
AML 42A, 29% in NCRI AML16 trial of older adults) and comparable to those of patients achieving 
CRMRD-  post first induction in the NCRI studies (3 year OS if CRMRD-, 69% in NCRI AML17, 73% in 
HOVON/SAKK AML 42A, 42% in NCRI AML16).   
We note that outcomes were very similar for refractory/MRD- younger adults between the NCRI and 
HOVON trials; this was also true for the refractory/MRD+ subgroup.  Thus from the results of two 
independent cohorts, the predictive value of flow cytometric MRD in refractory adults appears robust 
and comparable despite variation in the flow cytometric MRD methodology and criteria for a positive 
test. 
 
Misclassification as refractory at induction can result in unnecessary treatment. The above results 
substantiate in adults the ELN statement that ‘remission status as assessed by flow cytometry provides 
a more reliable predictor of outcome than conventional morphology-based CR assessment (Dohner, 
et al 2017).   
It is therefore logical to propose that a morphological differential cell count should no longer be a 
requirement for CR classification of induction response when a representative (‘first pull’) bone 
marrow sample is MRD negative by a validated flow cytometric MRD assay from experienced 
laboratories.   
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Table 1  
 
 
 
Younger Adults Older Adults 
NCRI UK AML17(Freeman, et al 2018) 
 
HOVON/SAKK AML 42A11 
 
NCRI UK AML166 
 
Post 1st Induction   
 
 
N=259 
 
 
 
N=81 
 
 
 
 
N=79 
 
 
Patients ‘Not in CR 
with MFC-MRD data’ 
 
 
 
 
 
No.  (% ) 
 
 
3 year OS  
 
Median OS 
 
 
 
3 year CIR 
 
3 year RFS 
 
 
No.  of CR1 
transplants 
 
 
Not in CR but  
MFC-MRD- 
 
 
25 (9.7%) 
  
 
61% 
 
57 months 
 
 
 
26% 
 
63% 
 
 
8 allo 
 
  
 
Not in CR and 
MFC-MRD+ 
  
     
 234 (90.4%) 
 
 
33% 
 
16 months 
 
 
 
52% 
 
36% 
 
 
102  allo   
 
 
 
Not in CR but  
MFC-MRD- 
 
  
25 (30.9%) 
 
 
60% 
 
Not reached with 
median follow-up 
of 31 month 
 
32% 
 
56% 
 
 
5 allo 
9 auto 
 
 
Not in CR and 
MFC-MRD+ 
 
     
56 (69.1%) 
 
 
27% 
 
14 months 
 
 
 
54% 
 
34% 
 
 
22 allo 
9  auto 
 
 
Not in CR but  
MFC-MRD- 
 
  
21 (20.8%) 
 
 
35% 
 
 
Not in CR and 
MFC-MRD+ 
     
  
80 (79.2%) 
 
 
<10%  
 
 
  
Patients in CR but  
≥5% blasts by 
 flow cytometry 
 
N= 7 
6 died within 2 years 
N=3 
1 died within 2 years 
N=15 
All dead by 20 months 
 
 
CR, Complete Remission by morphology; MFC-MRD, measurable residual disease by flow cytometry; MFC- MRD+, MRD positive;  
MFC-MRD- , MRD negative; OS, overall survival; CIR, cumulative incidence of relapse; RFS, relapse free survival; CR1 transplant, transplant 
in first remission.   
 
 
 
 
